Breast/Evaluation of Cryotherapy and TRPA1 Receptors in Chemotherapy Induced Neuropathy

Inclusion Criteria: * Histologically confirmed diagnosis of early stage breast cancer (stage I-III). * Planned to receive treatment with either adjuvant or neo-adjuvant taxane-based chemotherapy. * Age \> 18 years. There is no upper age limit for participation in this study. * Patients may have received any of the following therapies: surgery, chemotherapy, hormones, biologics, or radiation. * Prior chemotherapies are permitted, except with prior treatments with taxanes, vinca alcaloids, gemcitabine, eribulin, ixabepilone, platinum drugs) * All patients will have given signed, informed consent prior to registration * Patients must have a performance status of ECOG 0 or 1. Exclusion Criteria * Patients must not have received any prior taxane or platinum based chemotherapy. * Patients must not have a history of peripheral neuropathy (regardless of cause). * Patient must not have a history of Raynaud's disease. * Patients with partial or complete limb amputations. * Known hypersensitivity to cold * Patient cannot be on the following medications: GABA analogues (such as Neurontin, lyrica), tricyclic antidepressants (such as amitriptyline or nortriptyline) * As judged by the investigator, severe uncontrolled concurrent medical conditions, psychiatric illness or social condition that would limit compliance with study requirements. * Evidence of any significant clinical disorder or laboratory finding that makes it undesirable for the subject to participant in the clinical trial * Must not be pregnant or breast feeding